$WBI

Raymond James raises WaterBridge Infrastructure price target on growth

Raymond James raised its price target on WaterBridge Infrastructure (NYSE:WBI) to $40 from $35, citing strong growth and strategic relationships. The company reported Q2 2026 adjusted EBITDA of $116M, exceeding estimates, and raised its 2026 guidance. WBI's stock has surged 59% year-to-date, trading below its fair value. JPMorgan also initiated coverage with an Overweight rating and a $38 price target.

Original reporting
Published Aug 18, 2026, 5:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 7:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$WBI
Bullish
medium confidence
Mentioned
$WBI
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$WBIBullishMed
01

Why it matters

For traders, the actionable element is the PT increase to $40 from $35 alongside a Strong Buy stance, supported by a Q2 adjusted EBITDA beat and higher 2026 EBITDA and volume guidance.

02

Market read

A valuation reset via PT increase, anchored to reported Q2 results and raised 2026 guidance, can drive incremental positioning in WBI even if it is not a new earnings print.

03

What to watch

Key risks are execution on Speedway ramp and the sustainability of volume and revenue-per-barrel trends; the text also notes a prior EPS miss, which could cap upside if margins or cash conversion disappoint.

Relevance 7/10Novelty 6/10Timing: today’s analyst price-target update

Background

The piece frames WBI’s valuation and growth outlook through Raymond James’ updated target, referencing Q2 2026 operating metrics and raised 2026 guidance.

Company-level read

Ticker impact

$WBIBullishMedium confidence
Context

Raymond James raised WaterBridge Infrastructure’s price target to $40 from $35 and kept a Strong Buy rating, citing growth in produced-water management.

Expected impact

Mildly positive drift risk for WBI as traders reprice the Street’s valuation framework around the updated target and guidance narrative.

Evidence & confidence

The article provides specific PT change and ties it to reported Q2 EBITDA beat, produced-water volume growth, and raised 2026 guidance, which can influence positioning even without a fresh earnings release in the text.

Market effects

Reinforces positive sentiment for produced-water and oilfield services-adjacent infrastructure names tied to Delaware Basin activity and organic growth narratives.

Limited direct regional impact; story is US-focused on Delaware Basin operations.

Low; primarily a single-name valuation and guidance read-through.

Counterpoint

The article’s core catalyst is an analyst PT raise, so the market may already be pricing the guidance and Q2 beat given the stock’s strong YTD run.

Key entities

  • WaterBridge Infrastructure

    Subject of the analyst price-target raise, with Q2 EBITDA beat and raised 2026 guidance discussed.

  • Raymond James

    Raised WBI’s price target to $40 from $35 and maintained Strong Buy.

  • LandBridge

    Described as a sister company in a strategic relationship supporting WBI’s platform narrative.

  • JPMorgan

    Resumed coverage with Overweight and a $38 price target, per the article.

Related articles

$WBIMed

WaterBridge (WBI) Raised Guidance Again, So Why Did Shares Slip?

WaterBridge Infrastructure (NYSE:WBI) reported record quarterly revenue of $217.8 million and raised full-year adjusted EBITDA guidance to $435 million to $475 million. It also increased volume guidance to 2.55 million to 2.75 million bpd after acquisitions. Despite the upgrades, shares fell about 1.73% as capex rose to $530 million to $590 million and leverage reached 3.3x.

MedAI 8/10

WaterBridge Infrastructure (WBI) Q2 2026 Earnings Call Transcript

WaterBridge Infrastructure (WBI) reported Q2 2026 revenue of $217.8 million (+8% sequential) and net income of $14.6 million. Adjusted EBITDA rose to $115.8 million, with margin improving to 53%. Full-year 2026 guidance was raised for volume (2.55-2.75 mbpd) and adjusted EBITDA ($435-$475m) after the Ranger Water Midstream and NDB Landfill acquisitions.

$WBIMedAI 8/10

WBI Q2 Earnings Call Highlights

WaterBridge (NYSE:WBI) expanded its revolving credit facility to $750 million from $500 million, with capacity up to $1 billion, and said borrowing costs fell by 25 bps. It raised 2026 guidance to 2.55-2.75 mbpd and adjusted EBITDA of $435-$475 million, increased capex to $530-$590 million, and declared a $0.05/share dividend.

$WBIMed

WaterBridge Infrastructure LLC (WBI) (Q2 2026) Earnings Call Highlights: Record Revenue

WaterBridge Infrastructure LLC’s Q2 2026 earnings call covered landfill and produced-water strategy. CEO Jason Long discussed acquiring NDB for solid-waste growth and regulatory advantages, and COO Michael Choff-Wrights said Ranger could add throughput to the Speedway system without overcommitting capacity. CFO Scott McNeely cited conservative guidance, potential produced-water treatment for hyperscalers, and Speedway Phase 1 ramping toward ~100,000 bpd.

$WBIHigh

WaterBridge Infrastructure LLC (WBI): Results of Operations and Financial Condition

WaterBridge Infrastructure LLC (WBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 WaterBridge Announces Second Quarter 2026 Results Reports second quarter 2026 produced water handling volumes of 2.6 million barrels per day and revenue of $217.8 million, representing quarter-over-quarter growth of 6% and 8%, respectively Announces strategic acquisi

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.